KG is required for the activity of KG-dependent dioxygenases 2 (KGDDs), and previous work has focused almost exclusively on the demethylase functions of KGDD
Retatrutide's Phase 3 program started in 2024, so a 2027 to 2028 obesity approval lines up cleanly with the same four-year arc
LY354740 is a potent and highly selective group II metabotropic glutamate receptor agonist in cells expressing human glutamate receptors
Most people who look into it have already spent years trying to eat better, stay active, and do the right things but still feel like progress is harder than it should be
Anastasaki C, Wegscheid ML, Hartigan K, Papke JB, Kopp ND, Chen J, et al
Use a licensed-provider review to connect the comparison with eligibility, safety, and access